This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Psychiatry, Other  • Alert me on articles by topic

Arch Gen Psychiatry. 1999;56:353-354.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE REPORT by the Institute of Medicine (IOM)¹ was developed from an IOM study requested and funded by the US Food and Drug Administration (FDA). It was prompted by the controversy over the approval process for triazolam (Halcion; Upjohn Co, Kalamazoo, Mich). Although an FDA task force already considered the drug safe and effective when used according to the labeling, an independent panel was considered necessary.

The charge to the IOM goes beyond the usual concerns of the FDA about the adequacy of the pivotal clinical trials in a request for drug approval. The FDA further wishes the IOM to comment on the quality and quantity of postmarketing data, confidence in data on the effectiveness and adverse effects of Halcion at different doses and for different durations, and the need for additional studies.

This is of particular interest because the FDA has previously held itself to be primarily a regulatory . . . [Full Text of this Article]

RELATED ARTICLES

Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion
William E. Bunney, Jr, Daniel L. Azarnoff, Byron W. Brown, Jr, Robert Cancro, Robert D. Gibbons, John C. Gillin, Sandral Hullett, Keith F. Killam, David J. Kupfer, John H. Krystal, Paul D. Stolley, Geoffrey S. French, and Andrew M. Pope
Arch Gen Psychiatry. 1999;56(4):349-352.
EXTRACT | FULL TEXT  

Long-term Use of Sedative and Hypnotic Medication
David L. Dunner
Arch Gen Psychiatry. 1999;56(4):355.
EXTRACT | FULL TEXT